Clinical Trials
3 trialsNCT03919175 2026-02-27
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT04508647 2024-03-21
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma
University of Colorado, Denver
Phase 2 Completed
NCT04635683 2022-09-30
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn